Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
- W. Park, Nak-Hyun Kim, +9 authors Kyung-Sang Yu
- Medicine
- Clinical infectious diseases : an official…
- 15 October 2012
BACKGROUND
Blood levels of voriconazole, a first line therapy for invasive aspergillosis, may correlate with adverse events and treatment response. However, no randomized controlled studies have been… Expand
Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
- Bo-Hyung Kim, Hyeong-Seok Lim, +8 authors I. Jang
- Medicine
- British journal of clinical pharmacology
- 1 June 2008
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
The phosphodiesterase (PDE) type 5 inhibitor is a widely used agent that facilitates penile erection. Udenafil is newly developed as a PDE-5 inhibitor.
WHAT… Expand
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states
- Kyung-Sang Yu, Joo-Youn Cho, +9 authors S. Shin
- Medicine
- Clinical pharmacology and therapeutics
- 1 August 2004
Our objective was to investigate the effect of the CYP3A5 genotype on the systemic clearance of midazolam in constitutive, inhibited, and induced metabolic conditions.
Effect of the UGT2B15 Genotype on the Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Intravenous Lorazepam in Healthy Volunteers
- Jae-Yong Chung, Joo-Youn Cho, +5 authors S. Shin
- Medicine
- Clinical pharmacology and therapeutics
- 1 June 2005
Our objective was to investigate the effect of the uridine 5′‐diphosphate‐glucuronosyltransferase (UGT) 2B15 genetic polymorphism on the pharmacokinetics and pharmacodynamics of lorazepam in basal,… Expand
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
- Jae-Yong Chung, Joo-Youn Cho, +7 authors I. Jang
- Biology, Medicine
- Clinical pharmacology and therapeutics
- 1 October 2005
Pitavastatin is a potent, newly developed 3‐hydroxy‐3‐methylglutaryl–coenzyme A reductase inhibitor for the treatment of hyperlipidemia. We characterized the effects of organic anion transporting… Expand
A variant 2677A allele of the MDR1 gene affects fexofenadine disposition
- So-Young Yi, K. Hong, +8 authors S. Shin
- Medicine
- Clinical pharmacology and therapeutics
- 1 November 2004
There have been considerable disagreements regarding the influence of MDR1 (ABCB1) polymorphisms on the disposition of P‐glycoprotein (P‐gp) substrates. We speculated that the unknown function of the… Expand
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
- S. Lee, Bo-Hyung Kim, +5 authors Kyung-Sang Yu
- Medicine
- Journal of clinical pharmacology
- 1 February 2012
The current study assessed the influence of the CYP2C19 genotype on the pharmacokinetics and tolerability of voriconazole after single and multiple oral doses in healthy volunteers. Six subjects for… Expand
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
- J. Kim, Hyo-Bum Seo, +7 authors I. Jang
- Biology, Medicine
- British journal of clinical pharmacology
- 1 December 2008
AIMS
The aims of this study were to develop a combined population pharmacokinetic model for both aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients and to identify… Expand
HAPLOTYPE STRUCTURE AND ALLELE FREQUENCIES OF CYP2B6 IN A KOREAN POPULATION
- Joo-Youn Cho, Hyeong-Seok Lim, +4 authors I. Jang
- Biology, Medicine
- Drug Metabolism and Disposition
- 1 December 2004
Cytochrome P450 2B6 (CYP2B6) metabolizes a number of therapeutic drugs and its metabolic activity varies markedly in human liver. Although genetic polymorphisms of CYP2B6 have been reported in… Expand
Effects of Pregnane X Receptor (NR1I2) and CYP2B6 Genetic Polymorphisms on the Induction of Bupropion Hydroxylation by Rifampin
- J. Y. Chung, Joo-Youn Cho, +5 authors I. Jang
- Biology, Medicine
- Drug Metabolism and Disposition
- 1 January 2011
We investigated genetic polymorphisms in the pregnane X receptor (NR1I2) in Korean individuals (n = 83) and the effects of NR1I2 genotypes on rifampin-mediated induction of bupropion hydroxylation.… Expand